Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9403040 | 0.75 | — | — | |
| SCHEMBL17714593 | 0.75 | — | — | |
| SCHEMBL9403034 | 0.75 | — | — | |
| SCHEMBL6599340 | 0.67 | CA4 (0.35) | TSHR | |
| SCHEMBL6599338 | 0.67 | CA4 (0.35) | TSHR | |
| SCHEMBL759355 | 0.65 | — | — | |
| SCHEMBL11601353 | 0.61 | — | — | |
| Carbon Tetrachloride SCHEMBL16469582 | 0.60 | TSHR (0.73) | TSHRCASP1 | |
| SCHEMBL5572189 | 0.60 | — | — | |
| SCHEMBL1614696 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2925738-B1 | CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF | GFBIOCHEMICALS LTD (MT) | 2018-01-10 | — | — | EP | disclosed |
| US-9458414-B2 | Cleaning, surfactant, and personal care compositions | GFBIOCHEMICALS LIMITED (MT) | 2016-10-04 | — | — | US | disclosed |
| US-9156809-B2 | Carboxy ester ketals, methods of manufacture, and uses thereof | SEGETIS, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| EP-2925738-A1 | CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF | Segetis, Inc. (US) | 2015-10-07 | — | — | EP | disclosed |
| US-20150252302-A1 | CLEANING, SURFACTANT, AND PERSONAL CARE COMPOSITIONS | SEGETIS, INC. (US) | 2015-09-10 | — | — | US | disclosed |
| US-8828917-B2 | Carboxy ester ketal removal compositions, methods of manufacture, and uses thereof | SEGETIS, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| WO-2014085609-A1 | CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF | SEGETIS, INC. (US) | 2014-06-05 | — | — | WO | disclosed |
| US-20140147395-A1 | CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF | SEGETIS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| WO-2014047428-A1 | CLEANING, SURFACTANT, AND PERSONAL CARE COMPOSITIONS | SEGETIS, INC. (US) | 2014-03-27 | — | — | WO | disclosed |
| EP-2603836-A2 | CARBOXY ESTER KETAL REMOVAL COMPOSITIONS, METHODS OF MANUFACTURE, AND USES THEREOF | Segetis, Inc. (US) | 2013-06-19 | — | — | EP | disclosed |
| WO-2012021824-A2 | CARBOXY ESTER KETAL REMOVAL COMPOSITIONS, METHODS OF MANUFACTURE, AND USES THEREOF | SEGETIS, INC. (US) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040880-A1 | CARBOXY ESTER KETAL REMOVAL COMPOSITIONS, METHODS OF MANUFACTURE, AND USES THEREOF | SEGETIS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147395-A1 | CARBOXY ESTER KETALS, METHODS OF MANUFACTURE, AND USES THEREOF | C9, C5, C1S | TSHR 3990/4885CASP1 809/4885 |
| US-20120040880-A1 | CARBOXY ESTER KETAL REMOVAL COMPOSITIONS, METHODS OF MANUFACTURE, AND USES THEREOF | CRAT, KDM6A, KAT6A | TSHR 3827/4885CASP1 801/4885 |
| US-20150252302-A1 | CLEANING, SURFACTANT, AND PERSONAL CARE COMPOSITIONS | ADH1C, C5, KAT7 | TSHR 1209/4885CASP1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.